<DOC>
	<DOCNO>NCT01562314</DOCNO>
	<brief_summary>Ulcerative Colitis inflammatory bowel disease ( IBD ) effect large amount population . The common treatment condition 5-aminosalicylic acid ( 5-ASA ) , however patient fail respond incur flare often escalate steroidal treatment . This study conduct GW Pharma Ltd pilot study order determine efficacy safety GWP42003 ( 0mg - 250mg twice daily ) , compare placebo , percentage participant achieve remission quantify Mayo score 2 less ( subscore &gt; 1 ) 10 week treatment . This first study determine whether study medication positive benefit subject ulcerative colitis symptom control , well effect inflammatory marker cytokine ( plasma tumour necrosis factor [ TNF ] α , interleukin [ IL ] -2 , IL-6 ) , C reactive protein [ CRP ] , faecal inflammatory marker ( calprotectin ) , stool frequency ( NRS ) , rectal bleeding ( NRS ) , pain ( NRS ) . In addition , various IBD questionnaire implement study observe benefit study medication , compare placebo . This study multi-centre , randomise , double-blind , placebo-controlled , parallel-group pilot study . There two parallel group participant ( 0mg-250mg GWP42003 placebo , twice daily ) , treatment duration 10 week well 7 day baseline period one week follow-up . The two treatment group 0mg-250mg GWP42003 placebo randomise equally 1:1 ratio , 31 participant active IMP group 31 participant allocate placebo treatment . In order eligible enrollment study , subject need age 18 year ( 18-65 Czech Republic ) clinically diagnose mild moderate ulcerative colitis fix dose 5-ASA treatment ( 0 mg dose 5-ASA acceptable ) stable dose least 2 week prior screen . Eligible subject enter study screen visit ( Visit 1 ) commence baseline period . Each subject Mayo ( include endoscopy ) assessment conduct confirm eligibility . If eligible , subject randomise 10-week treatment phase . There total 6 visit study .</brief_summary>
	<brief_title>A Pilot Study GWP42003 Symptomatic Treatment Ulcerative Colitis ( GWID10160 )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Male female participant age 18 year ( 1865 Czech Republic ) ; Participant diagnose mild moderate ulcerative colitis fix dose 5ASA treatment stable dose least 2 week prior screen ( 0 mg dose 5ASA acceptable ) ; Participants screen ( Visit 1 ) baseline ( Visit 2 ) Mayo assessment score great equal 4 ( ≥ 4 ) less equal 10 ( ≤ 10 ) endoscopy score least 1 ( ≥ 1 ) , follow adequate exposure oral and/ topical 5ASA , opinion investigator ; In opinion investigator , capable complying study requirement complete study ; Willing able give inform consent ; Willing name notify responsible authority participation study , applicable ; Willing allow primary care practitioner consultant , appropriate , notified participation study ; Severe ulcerative colitis ( Mayo score great 10 ( &gt; 10 ) ) ; Ulcerative colitis affect rectum i.e . Proctitis Gastrointestinal infection evident stool culture test clostridium difficile toxin ( opinion investigator ) ; Currently use use recreational cannabis , medicinal cannabis , cannabinoid medication ( include Sativex® ) , synthetic cannabinoid base medication within one month prior study entry unwilling abstain duration study ; Any know suspected history : alcohol substance abuse epilepsy recurrent seizures hypersensitivity cannabinoids ; Receiving prohibit medication prior screen ( Visit 1 ) duration study ; Previous nonresponders mono polyclonal antiTumour Necrosis Factor antibody ; Personal first degree relative , history schizophrenia psychosis ; History significant psychiatric disorder severe personality disorder ( discretion investigator ) ; Any know suspected history depression sufficient require treatment antidepressant disrupt ordinary life ( exclude episode reactive depression discretion investigator ) ; Clinically significant cardiac , renal hepatic impairment opinion investigator ; Female participant pregnant , lactate plan pregnancy course study 3 month date last dose ; Female participant child bear potential , unless willing use two form contraception , one must barrier contraception ( e.g . female condom occlusive cap ( diaphragm cervical vault/caps ) spermicide ) study 3 month date last dose ( however male condom use conjunction female condom ) ; Male participant whose partner child bear potential , unless willing use appropriate barrier method contraception ( condom spermicide ) addition female partner use another form barrier contraception ( e.g . occlusive cap ( diaphragm cervical vault/caps ) spermicide ) study 3 month date last dose ( however male condom use conjunction female condom ) ; Travel outside country residence plan treatment phase study ; Received Investigational Medicinal Product ( IMP ) within 30 day prior screen visit ; In opinion investigator , consider suitable study ; Any significant disease disorder , opinion investigator , may either put participant risk participation study , may influence result study , participant 's ability participate study ; Following physical examination , participant abnormality , opinion investigator would prevent participant safe participation study ; Unwilling abstain donation blood study ; Participants previously randomise study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Mild Moderate Ulcerative Colitis</keyword>
</DOC>